Wei Zou

US Patent:

20220412981, Dec 29, 2022

Filed:

Mar 4, 2022

Appl. No.:

17/686565

Inventors:

- South San Francisco CA, US
- Cambridge MA, US
Priti HEGDE - South San Francisco CA, US
Marcin KOWANETZ - San Francisco CA, US
David SHAMES - South San Francisco CA, US
Philip J. STEPHENS - Cambridge MA, US
James Xin SUN - Cambridge MA, US
Roman YELENSKY - Newton MA, US
Wei ZOU - South San Francisco CA, US

International Classification:

G01N 33/574
C07K 16/28
C12Q 1/6886
A61P 35/04
A61P 35/00
A61K 38/17
A61K 39/395
A61K 45/06
C07K 14/705

Abstract:

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

US Patent:

20210292851, Sep 23, 2021

Filed:

Jul 29, 2019

Appl. No.:

17/263708

Inventors:

- Pleasanton CA, US
- South San Francisco CA, US
John Palma - Alamo CA, US
Namrata Patil - South San Francisco CA, US
Johnny Wu - Castro Valley CA, US
Stephanie Yaung - San Jose CA, US
Wei Zou - San Carlos CA, US

International Classification:

C12Q 1/6886
C12Q 1/6869

Abstract:

The invention is a method of determining a likelihood that a cancer patient will respond to immunotherapy based on a mutation metric obtained by sequencing a small panel of nucleic acid targets in patient's cell-free DNA.

US Patent:

20200157635, May 21, 2020

Filed:

Oct 3, 2019

Appl. No.:

16/591813

Inventors:

- South San Francisco CA, US
Mahrukh HUSENI - Union City CA, US
Wei ZOU - San Carlos CA, US

International Classification:

C12Q 1/6886
G01N 33/50
C07K 16/28

Abstract:

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer. The invention is based, at least in part, on the discovery that an immune-score expression level based on one or more of PD-L1, CXCL9, IFNG, GZMB, CD8A, and PD-1 in a sample obtained from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)).

US Patent:

20190219586, Jul 18, 2019

Filed:

Apr 1, 2019

Appl. No.:

16/371589

Inventors:

- South San Francisco CA, US
- Cambridge MA, US
Priti Hegde - South San Francisco CA, US
Marcin Kowanetz - South San Francisco CA, US
David Shames - South San Francisco CA, US
Philip J. Stephens - Cambridge MA, US
James Xin Sun - Cambridge MA, US
Roman Yelensky - Newton MA, US
Wei Zou - South San Francisco CA, US

International Classification:

G01N 33/574
A61P 35/00
C07K 16/28
C07K 14/705
A61K 45/06
C12Q 1/6886
A61K 39/395
A61K 38/17
A61P 35/04

Abstract:

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).